Stock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating

Stock Track

2024/11/18

Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.

The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.

Intellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1126356414"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126356414\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126356414?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126356414","market":"us","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating","media":"Stock Track","content":"<p>Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.</p>\n\n<p>The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.</p>\n\n<p>Intellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-18 16:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.</p>\n\n<p>The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.</p>\n\n<p>Intellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1126356414","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126356414","pubTimestamp":1731919100,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Intellia Therapeutics  soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.Intellia is a leading gene editing company focused on devel","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"股票跟踪Intellia Therapeutics因药物数据乐观和分析师评级看涨而飙升18.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.\nThe rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.\nIntellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}